Cyclin-dependent kinases (CDKs) belong to a protein serine/threonine kinases whose activity depends on association with a noncatalytic regulatory subunit called a cyclin. Cyclin-dependent kinases inhibitors are vital for progression through the cell cycle and proliferation.
INTRODUCTION
Definition
history
DIFFERENT PHASE
G0 PHASE
INTERPHASE
M PHASE
CHECKPOINT
HOW DOES IT WORK
Inhibitors
Mechanism of action
Function
CONCLUSION
references
it is bypass cycle of citric acid cycle.
it give the brief description of glyoxylate cycle.
it is the summary of glyoxylate cycle for m.sc, bsc, science students.
it is very important topic for entrance exam of biology stream.
INTRODUCTION
Definition
history
DIFFERENT PHASE
G0 PHASE
INTERPHASE
M PHASE
CHECKPOINT
HOW DOES IT WORK
Inhibitors
Mechanism of action
Function
CONCLUSION
references
it is bypass cycle of citric acid cycle.
it give the brief description of glyoxylate cycle.
it is the summary of glyoxylate cycle for m.sc, bsc, science students.
it is very important topic for entrance exam of biology stream.
Cytoskeleton - microtubules ,microfilaments and intermediate filamentsBIOTECH SIMPLIFIED
The cytoskeleton is a structure that helps cells maintain their shape and internal organization, and it also provides mechanical support that enables cells to carry out essential functions like division and movement. There is no single cytoskeletal component. Rather, several different components work together to form the cytoskeleton.
Nucleus: Structure and function
nuclear membrane
nuclear lamins
Nuclear pore complexe
nuclear matrix, composition and its role
cajal bodies
SFCs
nuclear speckles
PML bodies
Nucleolus
cell lineage , cell fate - diverse class of cell fate, cell fate in plant meristem, mammalian development cell fate, nutritional effects on epigenetics, epigenetics of plants,
control of cell fate.
Details of cytoskeleton element-microtubule. The Microtubule associated protein-type and function, Treadmilling and dynamic instability, Structure of cilia and flagella
Cytoskeleton - microtubules ,microfilaments and intermediate filamentsBIOTECH SIMPLIFIED
The cytoskeleton is a structure that helps cells maintain their shape and internal organization, and it also provides mechanical support that enables cells to carry out essential functions like division and movement. There is no single cytoskeletal component. Rather, several different components work together to form the cytoskeleton.
Nucleus: Structure and function
nuclear membrane
nuclear lamins
Nuclear pore complexe
nuclear matrix, composition and its role
cajal bodies
SFCs
nuclear speckles
PML bodies
Nucleolus
cell lineage , cell fate - diverse class of cell fate, cell fate in plant meristem, mammalian development cell fate, nutritional effects on epigenetics, epigenetics of plants,
control of cell fate.
Details of cytoskeleton element-microtubule. The Microtubule associated protein-type and function, Treadmilling and dynamic instability, Structure of cilia and flagella
The phenomenon of signal transduction, also known as cell signaling, pertains to the intricate mechanisms that facilitate the transfer of biological information between cells. The effective coordination of diverse specialized cell types in various tissues and organs is a prerequisite for the proper functioning of complex multicellular organisms, necessitating intercellular communication. This communication must be continuous and dynamic to maintain coordination. Additionally, cell signaling pathways play a crucial role in the mechanisms of action of numerous drugs, including both local and general anesthetics. Consequently, a fundamental understanding of cell signaling mechanisms is imperative for comprehending various pathophysiologic and pharmacologic mechanisms.
Please answer all of #5 After the completion of S phase, F.2F functi.pdfsiennatimbok52331
Please answer all of #5 After the completion of S phase, F.2F function is no longer needed. pRb
must be dephosphorylated so that it can once again bind to E2F. Name the type of enzyme
responsible for removing phosphate groups from proteins. Knowing what you know about the
cell cycle, explain why the RB gene would be considered a tumor suppressor gene. Below are
listed four different mechanisms of regulating of cyclin/CDK activity. For each mechanism
explain how that mechanism regulates cyclin/CDK activity. Phosphorylation by WeeI
Dephosphorylation by Cdc 25 Binding by a cyclin dependent kinase inhibitor Degradation of
cyclins by the proteasome
Solution
5. A. Wee1 is a nuclear kinase belonging to the Ser/Thr family of protein kinases in the fission
yeast Schizosaccharomyces pombe (S. pombe). It has a molecular mass of 96 kDa and it is a key
regulator of cell cycle progression. It influences cell size by inhibiting the entry into mitosis,
through inhibiting Cdk1. It has homologues in many other organisms, including mammals.
Wee1 inhibits Cdk1 by phosphorylating it on two different sites, Tyr15 and Thr14. Cdk1 is
crucial for the cyclin-dependent passage of the various cell cycle checkpoints. At least three
checkpoints exist for which the inhibition of Cdk1 by Wee1 is important:
B. Cdc25 is a dual-specificity phosphatase first isolated from the yeast Schizosaccharomyces
pombe as a cell cycle defective mutant. As with other cell cycle proteins such as Cdc2 and Cdc4,
the \"cdc\" in its name refers to \"cell division cycle\". Dual-specificity phosphatases are
considered a sub-class of protein tyrosine phosphatases. By removing inhibitory phosphate
residues from target Cyclin-Dependent Kinases (Cdks), Cdc25 proteins control entry into and
progression through various phases of the cell cycle, including mitosis and S (\"Synthesis\")
phase.
Cdc25 activates cyclin dependent kinases by removing phosphate from residues in the Cdk
active site. Also, the phosphorylation of M-Cdk (a complex of Cdk1 and cyclin B) activates
Cdc25. Together with Wee1, M-Cdk activation is switch-like. The switch-like behavior forces
entry into mitosis to be quick and irreversible. Cdk activity can be reactivated after
dephosphorylation by Cdc25. The Cdc25 enzymes Cdc25A-C are known to control the
transitions from G1 to S phase and G2 to M phase.
C. A cyclin-dependent kinase inhibitor (CKI) is a protein that interacts with a cyclin-CDK
complex to block kinase activity, usually during G1 or in response to signals from the
environment or from damaged DNA. In animal cells, there are two major CKI families: the
INK4 family and the CIP/KIP family. The INK4 family proteins are strictly inhibitory and bind
CDK monomers. Crystal structures of CDK6-INK4 complexes show that INK4 binding twists
the CDK to distort cyclin binding and kinase activity. The CIP/KIP family proteins bind both the
cyclin and the CDK of a complex and can be inhibitory or activating. CIP/KIP family proteins
activate c.
This slideshow contains various stages of cell cycle regulation, cell cycle checkpoints and their proteins involved in regulation. Cell cycle checkpoints transition phases.
A cell cycle is a series of events that takes place in a cell as it grows and divides. The process has to be correct and regulated. This slide illustrated Cell cycle and its regulation. Check the slides to know more.
Dry AMD has the potential to progress to geographic atrophy, a stage characterized by irreversible vision loss caused by the depletion of crucial retinal components such as retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris in the macula.
Food Allergy Market Report 2032 by DelveInsightpharmdelve
As per DelveInsight, the Food Allergy Market is expected to expand at a healthy growth rate during the forecast period (2023-2032), owing to the launch of new therapies in the market and the rise in the number of cases.
Functional dyspepsia is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms.
Cluster Headache Market Trends, Market Size and Share, Epidemiology and Marke...pharmdelve
Cluster Headache is a major headache and is very common in a group of head problems called trigeminal autonomic cephalalgias. The term cluster headache comes from the fact that the attack occurred in groups, or “clusters.” During the group cycle, severe headaches also occur between 1─8 times a day. Cluster cycles can last for weeks or months and are usually terminated during periods of remission, or periods of headaches. It usually occurs at the age of 20-40 and this condition is more common in men than women. It contains a headache on one side of the head. It is related to symptoms that occur on the same side of the head where the pain persists, runny or crooked nose, including red or clear eye, and spraying or sweating of the face.
Epilepsy is a neurological disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness.
As per the Delveinsight, in 2017, the Epilepsy market size in 7MM was USD 1,847.46 Million.
The total prevalent population of Epilepsy in 7MM was 7,190,297 in 2017. The total prevalent population of Epilepsy in the United States was found to be 3,579,732, while the United Kingdom and Germany had a prevalent population of 3,579,732 and 641,720 respectively.
Specialized multidisciplinary care, constructive efforts, promising emerging therapies, increase in R&D and government initiatives and funding are the key drivers for the Epilepsy market.
Some of the key companies in the Epilepsy market include Marinus Pharmaceuticals, Aquestive Therapeutics, Insys Therapeutics, Takeda/Ovid Therapeutics, Zynerba Pharma, Idorsia Pharmaceuticals, Neurocrine Biosciences, PTC Therapeutics, BioPharm Solutions, Biogen, Engage Therapeutics, Cerebral Therapeutics, Epygenix, Jazz Pharmaceuticals, Xenon Pharmaceuticals, Pfizer/ Cerevel Therapeutics, and Stoke Therapeutics.
Source:
Epilepsy Market
Hallux Valgus
Hallux Valgus, commonly known as a Bunion, is a deformity of the joint connecting the big toe to the foot. The big toe often bends towards the other toes and the joint becomes red and painful.
As per the Delveinsight, in 2017, the Hallux Valgus market size in 7MM was USD 6,254 million.
The total prevalent cases of Hallux Valgus in 7MM was 172,039,751 in 2017. The prevalent cases in the United States was found to be 70,259,180 while Germany and the United Kingdom had 18,748,873 and 14,374,384 prevalent cases respectively.
Increasing prevalence owing to increased use of tight, narrow fitted footwear majorly and availability of numerous treatment options are the key market drivers for Hallux Valgus.
Some of the key companies in the Hallux Valgus market include Syntellix, Treace Medical Concepts, Wright Medical Technology, Trilliant Surgical, Arthrosurface and Nextremity Solutions.
Source:
Hallux Valgus Market
Intrahepatic Cholangiocarcinoma (ICCA) is a subtype of cholangiocarcinoma, a rare and heterogeneous malignant neoplasm with the epithelial cell origin of the biliary duct and histologic and biochemical features of cholangiocyte differentiation.
In 2017, the market size of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM was USD 99.78 million.
The total incident population of Intrahepatic Cholangiocarcinoma (ICCA) in 7MM was 10,177 in 2017. The incident cases of ICCA in the US were found to be 3,639 while Italy and Germany had 1,111 and 1,101 incident cases of ICCA.
Rising Incidence, technological advancements in the identification of biomarkers and increasing R&D Activities are some of the key market drivers for Intrahepatic Cholangiocarcinoma.
Some of the key companies in the Intrahepatic Cholangiocarcinoma (ICCA) market includes Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology, QED Therapeutics, Janssen Pharmaceutical, Taiho Oncology, RedHill Biopharma, GlaxoSmithKline, Merck, Eisai, Taiho Pharmaceutical, Sorrento Therapeutics, Yuhan Corporation, Hutchison Medipharma, Jiangsu HengRui Medicine, AstraZeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, and Array BioPharma.
For more detailed information on Intrahepatic Cholangiocarcinoma Market, visit:
https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-market
Source:
Intrahepatic Cholangiocarcinoma Market
Gender Dysphoria is the feeling of discomfort or distress that might occur in people whose gender identity differs from their sex assigned at birth or sex-related physical characteristics.
In 2017, the therapeutic market of Gender Dysphoria in 7MM was USD 102.73 million.
As per the Delveinsight, the total prevalent population of Gender Dysphoria in the 7MM was 37,241 in 2017. The prevalence of Gender Dysphoria in the United States was found to be 12,521, while the UK and France had a prevalence of 8,214 and 1,544, respectively.
The absence of therapies in the market, increase in the affected population, poor efficacy, and side effects associated with current therapies are some of the key factors expected to drive the Gender Dysphoria market forward in the coming years.
Source:
Gender Dysphoria Market
Prurigo Nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution.
As per the Delveinsight, in 2017, the market size of Prurigo Nodularis in 7MM was USD 659.29 Million.
The total diagnosed prevalent population of Prurigo Nodularis in 7MM was 539,893 in 2017. Among the 7MM, the United States had the largest share of the total diagnosed prevalent population with ~46.30% of the total cases.
Government initiatives, pipeline advancements and various off-label therapies, growth in R&D and increase in the number of patients are the key drivers for Prurigo Nodularis Market.
The key companies in the Prurigo Nodularis Market includes Menlo Therapeutics, Trevi Therapeutics, Galderma, Amgen, Maruho, Kiniksa Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals and many others.
Source: Prurigo Nodularis Market
For more information on Prurigo Nodularis Market, visit:
https://www.delveinsight.com/report-store/prurigo-nodularis-market
Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults.
As per the Delveinsight, the market size of Glioblastoma Multiforme in the 7MM (i.e United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) was USD 1,005 Million in 2017.
The total diagnosed incident population of Glioblastoma Multiforme in seven major markets was 28,259 in 2017. It is observed that GBM is more prevalent among males than females in 7MM.
Robust pipeline activity, upcoming launches and approval, improved treatment deliverance, emergence of immunotherapies, advancements in genomics and proteomics, low cost of treatment, interventions that can cross the blood-brain-barrier are some of the key driver for the Glioblastoma Multiforme Market.
The key companies in the Glioblastoma Multiforme market includes VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Immunomic Therapeutics and Inovio Pharmaceuticals.
Source: Glioblastoma Multiforme (GBM) Market
For more information on Glioblastoma Multiforme (GBM) Market, visit:
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
Cystic Fibrosis is a life-limiting autosomal recessive genetic disorder that severely damages the lungs and the digestive system.
As per the Delveinsight, the total prevalent population of Cystic Fibrosis in 6MM was 61,306 in 2017. The prevalent population of Cystic Fibrosis in the UK was 10,468, while the US and Spain had a prevalent population of 30,139 and 2,075 respectively in 2017.
The Cystic Fibrosis market Size in the 6MM was found to be USD 1,940.1 million in 2017.
High number of drugs in the pipeline, better diagnostic techniques, most frequent mutation, and increased Research Funding are some of the key factors expected to drive the Cystic Fibrosis market forward in the coming years.
Some of the key companies in the Cystic Fibrosis market include Translate Bio, Proteostasis Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, ProQR Therapeutics, Ionis Pharmaceuticals, Verona Pharmaceuticals, Eloxx Pharmaceuticals, and many others.
For more details, visit:
https://www.delveinsight.com/report-store/cystic-fibrosis-market
Source : Cystic Fibrosis Market Analysis
In 2017, the total prevalent population of Epidermolysis Bullosa in 7MM was 41,509. The prevalent cases of Epidermolysis Bullosa in the United States was 26,104 in 2017, while the United Kingdom and Germany had 5,037 and 4,919 prevalent cases respectively.
The market size of Epidermolysis Bullosa in 7MM USD 2,283.40 million in 2017.
Robust pipeline, increase in funding for accelerating the development of novel therapies for Epidermolysis Bullosa treatment and encouraging organizations to develop promising therapies are some of the key factors expected to drive the Epidermolysis Bullosa Market forward in the coming years.
The key players in the Epidermolysis Bullosa Market includes Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, Castle Creek Pharmaceuticals, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Menlo Therapeutics and Phoenix Tissue Repair.
For more detailed information on Epidermolysis Bullosa Market, visit:
https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Osteosarcoma Market
In 2017, the total incident population of Osteosarcoma in 7MM was 2,181. The incident cases of Osteosarcoma in the United States was found to be 1,141 in 2017.
The therapeutic market of Osteosarcoma in 7MM was found to be USD 72.50 million in 2017.
Robust pipeline, increase in incidence and more Immunotherapies into clinical trials are some of the key factors expected to drive the Osteosarcoma Market forward in the coming years.
The key players in the Osteosarcoma Market includes Bayer, Exelixis, Nektar Therapeutics, Eisai, Y-mAbs Therapeutics, GlaxoSmithKline, Novartis, Aadi Bioscience, Vaccinex, Inc., Eleison Pharmaceuticals, Aurora biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb and Cellestia Biotech.
For more detailed information on Osteosarcoma Market, visit:
https://www.delveinsight.com/report-store/osteosarcoma-market
In 2017, the total prevalent population of Cervical Cancer in 7MM was 43,514. The prevalent cases of Cervical Cancer in the United States in 2017 was 32.07% of the total prevalent cases.
The therapeutic market of Cervical Cancer in the 7MM was found to be USD 330.59 million in 2017.
Advancements in treatment, improvement in preventive measures, and early detection of disease are some of the key factors expected to drive the Cervical Cancer Market forward in the coming years.
The key players in the Cervical Cancer Market includes Seattle Genetics, Genmab, AstraZeneca, Zeria Pharmaceutical, Regeneron Pharmaceutical, Sanofi, Advaxis, Iovance Biotherapeutics, Agenus, Roche, Akeso Biopharma, Vaccibody and Altor BioScience.
For more detailed information on Cervical Cancer Market, visit: https://www.delveinsight.com/infographics/cervical-cancer-market
In 2017, the total incident cases of Multiple Myeloma in 8MM was 85,971. The incident cases of Multiple Myeloma in the United States was found to be 30,271 in 2017.
The market size of Multiple Myeloma in 8MM was USD 14,111 million in 2017.
Increasing incidence rate, high adoption rate of newer therapies and an increase in the Geriatric Population are some of the key market drivers for Multiple Myeloma.
The key players in the Multiple Myeloma Market includes GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, AbbVie, Roche, Janssen Biotech, Nanjing Legend Biotech, Oncopeptides AB, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Celgene, RAPA Therapeutics, Pfizer, Cellectar Biosciences, BioLineRx, Aduro Biotech, ExCellThera, Takeda, Glenmark, Poseida Therapeutics, Amgen, Precision BioSciences, Juno Therapeutics, Molecular Partners AG, Cartesian Therapeutics, AstraZeneca, MorphoSys AG, I-Mab Biopharma and Chipscreen Biosciences.
For more detailed information on Multiple Myeloma Market, visit: https://www.delveinsight.com/report-store/multiple-myeloma-market
The total prevalent population of Cutaneous Lupus Erythematosus in the 7MM was 327,569 in 2017. The Cutaneous Lupus Erythematosus cases in the United States in 2017 was 182,765.
The Market Size of Cutaneous Lupus Erythematosus in 7MM was found to be USD 485.27 Million in 2017, according to DelveInsight, Cutaneous Lupus Erythematosus Market in the 7MM is expected to change during the study period.
Rising prevalence and awareness of the disease, refined clinical trial design, contemporary advances in R&D are some of the key factors expected to drive the cutaneous lupus erythematosus market forward in the coming years.
Some of the key players in the Cutaneous Lupus Erythematosus market include Biogen, Pfizer, Galapagos NV, Gilead Sciences, LEO Pharma/ Japan Tobacco, VIELABIO and many others.
For more detailed information on Cutaneous Lupus Erythematosus market, visit:
https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
In 2017, the total prevalent cases of Uveitis in the United States were 357,791. It was found that in the United States, Acute Anterior Uveitis accounted for 43% of the total cases of Uveitis in 2017.
The market size of Uveitis in the seven major markets (i.e the US, Germany, France, Italy, the UK, Spain and Japan) was found to be USD 1,045.9 Million in 2017, which is expected to increase during the forecast period.
Availability of ocular inserts, orphan drug status, introduction of biologic drugs, and rich emerging pipeline with diverse ROA and MOA are some of the key factors expected to drive the Uveitis market forward in the coming years.
The key players in the Uveitis market includes Aldeyra Therapeutics, Santen Pharmaceutical, Oculis, EyeGate Pharma, Novartis, Clearside Biomedical, Bristol-Myers Squibb, Sanofi, Eyevensys and many others.
For more details visit: https://www.delveinsight.com/report-store/uveitis-market
Cytokine Release Syndrome Market
The total number of patients who developed Cytokine Release Syndrome in the 7MM were 31 in 2017.
The market size of Cytokine Release Syndrome (CRS) in the seven major markets was found to be USD 0.16 Million in 2017.
Increasing incidence of Acute Cytokine Release Syndrome (CRS), increasing R&D activities, and non-competitive landscape are some of the key factors expected to drive the Cytokine Release Syndrome market in the upcoming years.
The key pharma companies in the Cytokine Release Syndrome (CRS) market includes Novartis, Swedish Orphan Biovitrum (Sobi), Incyte Corporation, Jazz pharmaceuticals, CytoSorbents and many others.
For more detailed information on Cytokine Release Syndrome Market, visit:
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market
#inflammatorysyndrome #Cytokinereleasesyndrome #CRS #inflammation #systemicinflammatoryresponsesyndrome #sHLH
The total incident cases of Acute Lymphocytic Leukemia in the 7MM were 10,341 in 2017. It is being observed that around 56% of age-specific incident cases of ALL were found to be in the age group of <20 years in 2017. Also, ALL is more frequent in males as compared to females.
The market size of Acute Lymphocytic Leukemia in the 7MM was found to be USD 1,246 Million in 2017.
Increasing focus towards the development of targeted therapies, rising occurrence of ALL, improvement in the diagnosis and awareness, and competitive landscape are some of the key factors expected to drive the ALL market in the coming years.
The key players in the Acute Lymphocytic Leukemia market includes Pharmacyclics, Takara Bio/ Otsuka, Jazz Pharmaceutical, Bellicum Pharmaceuticals, Precision BioSciences, Allogene Therapeutics, Novartis, Autolus, Janssen Pharmaceuticals, Gamida Cell, BioLineRx, Bristol-Myers Squibb, Pfizer, Fate Therapeutics, Gilead Sciences, Sanofi, TCR2 Therapeutics, Miltenyi Biotec, AbbVie and others.
For more detailed information on Acute Lymphocytic Leukemia Market, visit: https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
1. Cyclin-dependent kinase
Overview
Cyclin-dependent kinases (CDKs) belong to a protein serine/threonine kinases whose activity
depends on association with a noncatalytic regulatory subunit called a cyclin. Cyclin-dependent
kinases inhibitors are vital for progression through the cell cycle and proliferation. The genes that
encode CDKs were initially identified in screens for conditional mutants of Saccharomyces
cerevisiae which reversibly arrested at characteristic points in the cell cycle upon transfer to the
restrictive conditions. Cyclins were initially named for their periodic accumulation and
degradation (cycling) through the early cell cycles of fertilized sea urchin eggs. This research
identified a ubiquitous cell cycle engine responsible for coordinating cell growth, DNA replication,
and mitosis in the orderly fashion required to ensure the viability of progeny cells.
How Do Cyclin-dependent kinases regulate Cell Cycle?
All eukaryotes have a various cyclins, each of which acts during a specific stage of the cell cycle.
All cyclins are given names according to the stage at which they assemble with Cyclin-dependent
kinases. The classes of cyclins involves G1-phase cyclins, G1/S-phase cyclins, S-phase cyclins,
and M-phase cyclins. M-phase cyclins make M-CDK complexes and lead the entry of cell into
mitosis; G1 cyclins form G1-CDK complexes and drive the progress of cells through the G1 phase.
All Cyclin-dependent kinases present in equal amounts throughout the entire cell cycle. The cyclin
produce and malfunction change by stage with cell cycle advancement dependent on the new
cyclin molecules synthesis. The cells produce G1- and G1/S-cyclins at different times during the
G1 phase, and they produce M-cyclin molecules during the G2 phase. Cyclin degradation is
equally essential for advancement through the cell cycle. Specific enzymes fail cyclins at specific
times in the cell cycle. When cyclin levels go low, the corresponding CDKs become inoperative.
Cell cycle arrest can happen if cyclins fail to degrade.
Which Proteins Do Cyclin-dependent kinases transform?
Each of the cyclin-CDK complexes in a cell alters a particular group of protein substrates. Proper
phosphorylation of these substrates ought to happen at specific times in order for the cell cycle to
continue. Because cyclin-CDK complexes recognize multiple substrates, they can correlate the
various events that happen during each phase of the cell cycle. For example, at the start of S phase,
S-CDK catalyzes the phosphorylation of the proteins that start DNA replication by admitting DNA
replication complexes to make. During mitosis, M-CDKs phosphorylate a broad range of proteins.
These involve condensin proteins that are vital for the substantial condensation of mitotic
chromosomes, and lamin proteins, which make a stabilizing network under the nuclear membrane,
which dismantles during mitosis. M-CDKs also control the assembly of the mitotic spindle by
phosphorylating proteins that regulate microtubule behaviour. The effect of these coordinated
phosphorylation reactions is the final division of chromosomes during mitosis.
2. Hence, the life cycle of a cell is a prudently controlled series of events arranged by a suite of
enzymes and other proteins. The main controlling components of cell cycle regulation are cyclins
and CDKs. Depending on the occurrence and action of these proteins, the cell cycle can be fast or
sluggish and it may even stop altogether.